H.C. Wainwright analyst Swayampakula Ramakanth downgraded Surface Oncology (SURF) to Neutral from Buy with a $5 price target after the company announced that it has entered into an agreement to merge with Coherus BioSciences (CHRS) and be acquired in a stock-for-stock transaction for up to $65M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SURF:
- Surface Oncology implements 50% workforce reduction
- Coherus to Acquire Surface Oncology
- Coherus Biosciences, Surface Oncology enter definitive merger agreement
- Surface Oncology (SURF) Q1 Earnings Cheat Sheet
- Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue